Teva Pharmaceutical Industries Ltd. announced that the FDA has approved Cinquair (reslizumab) Injection, an interleukin 5 antagonist monoclonal antibody (IgG4...
No reduction in the frequency of clinical asthma exacerbations (CAEs).
Teva Pharmaceutical Industries Ltd. announced that the European Commission has granted marketing authorization for Cinqaero (reslizumab) (Cinqair in the US)...
Reslizumab (Cinqaero®; Cinqair®) is a humanized monoclonal antibody against interleukin-5 (IL-5), a cytokine mediator of eosinophilic airway inflammation.
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing...